Kinnate Biopharma Inc
F:6KB
Kinnate Biopharma Inc
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-03. The Company’s products include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The firm has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered ulcerative colitis (UC). CDK12 inhibitor candidate to target the treatment of ovarian carcinoma (OC), metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC).
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-03. The Company’s products include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The firm has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered ulcerative colitis (UC). CDK12 inhibitor candidate to target the treatment of ovarian carcinoma (OC), metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC).
